2 completed, 1 terminated. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Catalyst Biosciences: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders Coagulation Factor VIIa variant - Factor VII Deficiency, Glanzmann Thrombasthenia | Phase 1 / Phase 2 | Terminated | Catalyst Biosciences | 19 | 2021-05-17 | 2021-12-21 |
| Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B Coagulation Factor IX variant - Hemophilia B | Phase 2 | Completed | Catalyst Biosciences | 6 | 2019-06-18 | 2021-08-09 |
| Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B Coagulation Factor VIIa variant - Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | Phase 2 | Completed | Catalyst Biosciences | 11 | 2017-12-18 | 2021-09-23 |
Factor VII Deficiency (1) · Hemophilia B (1) · Thrombasthenia (1)
Russia (2) · South Africa (2) · Armenia (1) · Georgia (1) · India (1) · Italy (1) · Poland (1) · Ukraine (1) · United States (1)